Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide

Rhea-AI Summary

Labcorp (NYSE: LH) announced nationwide rollout of FDA-approved self-collection solutions for HPV and STI testing, available from April 7, 2025. The service will be accessible at over 2,200 Patient Service Centers and participating physician offices across the US.

The initiative addresses critical healthcare gaps, as one in four women are not up-to-date with cervical cancer screenings. With over 13,000 women diagnosed with cervical cancer annually and approximately 4,000 deaths, this preventable disease remains a significant concern. The self-collection option includes testing for HPV and STIs (chlamydia, gonorrhea, trichomonas, and mycoplasma genitalium).

Key features include:

• Physician-ordered testing with private collection options
• Available at 2,200 Labcorp PSC locations
• Electronic results delivery to both physician and patient
• Follow-up with physician required for positive results

Positive

• Expansion into new FDA-approved testing services enhances revenue potential
• Leverages existing infrastructure of 2,200 locations for service delivery
• Addresses underserved market with 25% of women behind on cervical cancer screening
• Potential to capture share of 2.4 million annual STI cases market

Negative

• Requires physician orders, limiting direct-to-consumer potential
• Success depends on patient adoption and physician referrals
• Faces potential competition from other diagnostic providers

News Market Reaction

-0.04%

1 alert

-0.04% News Effect

On the day this news was published, LH declined 0.04%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen)

BURLINGTON, N.C., April 1, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer nationwide a U.S. Food and Drug Administration (FDA) approved human papillomavirus (HPV) self-collection solution that can help women and their physicians asses the risk of developing cervical cancer. Labcorp will also offer a vaginal swab self-collect option for sexually transmitted infection (STI) testing. Both solutions are available by physician order and can be completed privately in a healthcare setting or at any one of Labcorp's 2,200 Patient Service Centers (PSCs) nationwide.

"Many patients delay or avoid necessary health screenings due to discomfort, stigma or time challenges, which can lead to health complications and further spread infections," said Dr. Brian Caveney, Labcorp's chief medical and scientific officer. "Labcorp is now offering self-collection at our PSCs and healthcare settings such as physician offices to break down these barriers. With convenient access to essential tests and screenings, patients can take control of their health, on their own terms, when it's most convenient for them."

Expanding Access to Cervical Cancer Screening
Each year in the U.S. more than 13,000 women are diagnosed with cervical cancer and approximately 4,000 die from this preventable disease. HPV testing is a crucial tool for preventing cervical cancer through early intervention and treatment. According to the U.S. Centers for Disease Control and Prevention (CDC), one in four women of screening age were not up to date with cervical cancer screening recommendations in 2021.

Traditionally, cervical cancer screening involves a healthcare provider collecting a specimen during a Pap smear and forwarding it to a laboratory for testing. In 2024, the FDA approved self-collection tests for cervical cancer screenings.

"Cervical cancer is preventable, yet screening rates among women in the United States are alarmingly low," said Dr. Caveney. "By offering an easily accessible and less invasive alternative, self-collection can help improve screening rates by easing the load on physicians and opening up additional access points to reach those who might avoid or not have access to traditional in-office exams."

A Convenient and Private Screening Option for STIs
Labcorp will also offer a vaginal swab self-collect option for STI testing, including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen). According to the CDC, 2.4 million cases of STIs were diagnosed and reported in 2023. Early detection can help minimize long-term effects for patients and increase the effectiveness of treatment.

"STI testing can feel intimidating or stigmatizing, which leads to delayed or skipped screenings. Providing a private and discreet self-collection option empowers individuals to take control of their sexual health and can expedite the diagnosis to treatment timeline, ultimately driving better health outcomes," said Dr. Caveney.

Key Features of Labcorp's HPV and STI Self-Collection Offerings:

• Self-collection for both HPV and STI testing can be ordered by a physician and completed in a healthcare setting or one of Labcorp's 2,200 PSC locations nationwide.
• Results are sent electronically to the ordering physician and to the patient via their Labcorp Patient account.
• If positive, patients should follow up with their physician to determine treatment.

Labcorp's new self-collect offerings will be made available beginning April 7. To learn more about self-collect, click here. To find a patient service center near you, visit: https://www.labcorp.com/labs-and-appointments.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.

 

 

View original content:https://www.prnewswire.com/news-releases/labcorp-to-offer-hpv-and-sti-self-collection-options-in-labcorp-patient-service-centers-and-participating-physician-offices-nationwide-302416985.html

SOURCE Labcorp

FAQ

When will Labcorp (LH) launch its HPV and STI self-collection testing service?

Labcorp will launch the self-collection testing service on April 7, 2025, across its nationwide network.

How many Labcorp locations will offer HPV and STI self-collection testing?

The service will be available at all 2,200 Labcorp Patient Service Centers nationwide.

What types of STI tests are included in Labcorp's self-collection offering?

The self-collection STI testing includes chlamydia, gonorrhea, trichomonas, and mycoplasma genitalium (Mgen).

What is the current cervical cancer screening compliance rate according to Labcorp's announcement?

According to the CDC data cited, 25% of women of screening age were not up to date with cervical cancer screening recommendations in 2021.

How many cervical cancer cases and deaths occur annually in the US according to Labcorp's release?

Over 13,000 women are diagnosed with cervical cancer annually, with approximately 4,000 deaths from this preventable disease.